Table 1.
Drug activity against all MRSA isolates and epidemiological groupsa
| Isolate(s) | Drug(s) | MIC range (μg/ml) | MIC50 (μg/ml) | MIC90 (μg/ml) |
|---|---|---|---|---|
| All isolates (n = 111) | Tedizolid | 0.12 to 0.5 | 0.5 | 0.5 |
| Linezolid | 0.5 to 4 | 2 | 2 | |
| Trimethoprim/sulfamethoxazole | ≤0.5/9.5 to >2/38 | ≤0.5/9.5 | >2/38 | |
| Tigecycline | 0.06 to >1 | 0.25 | 0.5 | |
| Levofloxacin | 0.12 to >4 | 4 | >4 | |
| Clindamycin | 0.06 to >16 | 0.12 | >16 | |
| Vancomycin | ≤0.25 to 4 | 0.5 | 1 | |
| Daptomycin | ≤0.5 to 2 | ≤0.5 | ≤0.5 | |
| Oxacillin | 0.12 to >4 | >4 | >4 | |
| Erythromycin | 0.12 to >8 | >8 | >8 | |
| Gentamicin | ≤0.06 to >16 | 0.25 | >16 | |
| ST5-MRSA-II (USA100) (n = 10) | Tedizolid | 0.25 to 0.5 | 0.5 | 0.5 |
| Linezolid | 1 to 2 | 2 | 2 | |
| Trimethoprim/sulfamethoxazole | ≤0.5/9.5 | ≤0.5/9.5 | ≤0.5/9.5 | |
| Tigecycline | 0.06 to 0.5 | 0.25 | 0.25 | |
| Levofloxacin | 4 to >4 | 4 | >4 | |
| Clindamycin | 0.06 to >16 | >16 | >16 | |
| Vancomycin | 0.5 | 0.5 | 0.5 | |
| Daptomycin | ≤0.5 | ≤0.5 | ≤0.5 | |
| Oxacillin | >4 | >4 | >4 | |
| Erythromycin | >8 | >8 | >8 | |
| Gentamicin | ≤0.06 to 8 | 0.25 | 0.5 | |
| ST36-MRSA-II (USA200/EMRSA16) (n = 10) | Tedizolid | 0.12 to 0.5 | 0.5 | 0.5 |
| Linezolid | 0.5 to 4 | 2 | 2 | |
| Trimethoprim/sulfamethoxazole | ≤0.5/9.5 | ≤0.5/9.5 | ≤0.5/9.5 | |
| Tigecycline | 0.06 to 0.25 | 0.25 | 0.25 | |
| Levofloxacin | 0.12 to >4 | >4 | >4 | |
| Clindamycin | 0.12 to >16 | >16 | >16 | |
| Vancomycin | ≤0.25 to 0.5 | 0.5 | 0.5 | |
| Daptomycin | ≤0.5 | ≤0.5 | ≤0.5 | |
| Oxacillin | >4 | >4 | >4 | |
| Erythromycin | >8 | >8 | >8 | |
| Gentamicin | 0.12 to 0.25 | 0.25 | >16 | |
| ST8-MRSA-IV (USA300) (n = 10) | Tedizolid | 0.25 to 0.5 | 0.5 | 0.5 |
| Linezolid | 2 to 4 | 2 | 4 | |
| Trimethoprim/sulfamethoxazole | ≤0.5/9.5 | ≤0.5/9.5 | ≤0.5/9.5 | |
| Tigecycline | 0.06 to 0.25 | 0.12 | 0.25 | |
| Levofloxacin | 0.12 to >4 | 0.25 | 4 | |
| Clindamycin | 0.06 to >16 | 0.12 | 0.12 | |
| Vancomycin | 0.5 to 1 | 0.5 | 1 | |
| Daptomycin | ≤0.5 to 0.5 | ≤0.5 | ≤0.5 | |
| Oxacillin | >4 | >4 | >4 | |
| Erythromycin | >8 | >8 | >8 | |
| Gentamicin | ≤0.06 to 1 | 0.25 | 0.5 | |
| ST1-MRSA-IV (USA400) (n = 10) | Tedizolid | 0.5 | 0.5 | 0.5 |
| Linezolid | 2 to 4 | 2 | 4 | |
| Trimethoprim/sulfamethoxazole | ≤0.5/9.5 | ≤0.5/9.5 | ≤0.5/9.5 | |
| Tigecycline | 0.12 to 0.5 | 0.25 | 0.25 | |
| Levofloxacin | 0.12 to 0.5 | 0.25 | 0.5 | |
| Clindamycin | 0.12 to 8 | 0.12 | 0.12 | |
| Vancomycin | 0.5 to 1 | 0.5 | 1 | |
| Daptomycin | ≤0.5 | ≤0.5 | ≤0.5 | |
| Oxacillin | 0.5 to >4 | >4 | >4 | |
| Erythromycin | 0.12 to >8 | 0.5 | >8 | |
| Gentamicin | 0.25 to 1 | 0.25 | 0.5 | |
| ST8-MRSA-IV (USA500) (n = 10) | Tedizolid | 0.25 to 0.5 | 0.5 | 0.5 |
| Linezolid | 2 | 2 | 2 | |
| Trimethoprim/sulfamethoxazole | ≤0.5/9.5 to >2/38 | ≤0.5/9.5 | >2/38 | |
| Tigecycline | 0.12 to 0.5 | 0.25 | 0.25 | |
| Levofloxacin | >4 | >4 | >4 | |
| Clindamycin | 0.12 to >16 | >16 | >16 | |
| Vancomycin | 0.5 to 1 | 0.5 | 1 | |
| Daptomycin | ≤0.5 to 0.5 | ≤0.5 | ≤0.5 | |
| Oxacillin | 0.5 to >4 | >4 | >4 | |
| Erythromycin | 0.25 to >8 | >8 | >8 | |
| Gentamicin | 0.25 to >16 | 0.5 | >16 | |
| ST5-MRSA-IV (USA800) (n = 10) | Tedizolid | 0.25 to 0.5 | 0.5 | 0.5 |
| Linezolid | 1 to 2 | 2 | 2 | |
| Trimethoprim/sulfamethoxazole | ≤0.5/9.5 to 0.5/9.5 | ≤0.5/9.5 | ≤0.5/9.5 | |
| Tigecycline | 0.06 to 0.25 | 0.12 | 0.25 | |
| Levofloxacin | 0.12 to 4 | 0.12 | 0.25 | |
| Clindamycin | 0.06 to >16 | 0.12 | >16 | |
| Vancomycin | 0.5 to 1 | 0.5 | 1 | |
| Daptomycin | ≤0.5 | ≤0.5 | ≤0.5 | |
| Oxacillin | 1 to >4 | >4 | >4 | |
| Erythromycin | 0.25 to >8 | >8 | >8 | |
| Gentamicin | 0.12 to 0.5 | 0.25 | 0.5 | |
| ST22-MRSA-IV (EMRSA15) (n = 10) | Tedizolid | 0.25 to 0.5 | 0.25 | 0.5 |
| Linezolid | 1 to 2 | 2 | 2 | |
| Trimethoprim/sulfamethoxazole | ≤0.5/9.5 | ≤0.5/9.5 | ≤0.5/9.5 | |
| Tigecycline | 0.06 to 0.25 | 0.25 | 0.25 | |
| Levofloxacin | 0.12 to >4 | >4 | >4 | |
| Clindamycin | 0.12 to >16 | 0.12 | 0.12 | |
| Vancomycin | 0.5 to 1 | 0.5 | 0.5 | |
| Daptomycin | ≤0.5 | ≤0.5 | ≤0.5 | |
| Oxacillin | 0.12 to >4 | >4 | >4 | |
| Erythromycin | 0.25 to >8 | >8 | >8 | |
| Gentamicin | 0.12 to 1 | 0.25 | 0.25 | |
| ST80-MRSA-IV (European community associated) (n = 10) | Tedizolid | 0.25 to 0.5 | 0.25 | 0.5 |
| Linezolid | 2 to 4 | 2 | 2 | |
| Trimethoprim/sulfamethoxazole | ≤0.5/9.5 | ≤0.5/9.5 | ≤0.5/9.5 | |
| Tigecycline | 0.12 to >1 | 0.12 | >1 | |
| Levofloxacin | 0.12 to >4 | 0.12 | 0.25 | |
| Clindamycin | 0.12 to >16 | 0.12 | 0.5 | |
| Vancomycin | 0.5 to 4 | 0.5 | 1 | |
| Daptomycin | ≤0.5 | ≤0.5 | ≤0.5 | |
| Oxacillin | 4 to >4 | >4 | >4 | |
| Erythromycin | 0.25 to >8 | 0.5 | >8 | |
| Gentamicin | 0.12 to 2 | 0.25 | 1 | |
| ST247-MRSA-I (Iberian clone) (n = 11) | Tedizolid | 0.25 to 0.5 | 0.25 | 0.25 |
| Linezolid | 1 to 2 | 1 | 2 | |
| Trimethoprim/sulfamethoxazole | ≤0.5/9.5 to >2/38 | ≤0.5/9.5 | ≤0.5/9.5 | |
| Tigecycline | 0.12 to 1 | 0.25 | 0.5 | |
| Levofloxacin | 4 to >4 | >4 | >4 | |
| Clindamycin | 0.12 to >16 | >16 | >16 | |
| Vancomycin | 0.5 to 1 | 1 | 1 | |
| Daptomycin | ≤0.5 to 1 | ≤0.5 | ≤0.5 | |
| Oxacillin | >4 | >4 | >4 | |
| Erythromycin | 0.5 to >8 | >8 | >8 | |
| Gentamicin | >16 | >16 | >16 | |
| ST239-MRSA-III (Brazilian clone) (n = 10) | Tedizolid | 0.12 to 0.5 | 0.25 | 0.5 |
| Linezolid | 1 to 2 | 2 | 2 | |
| Trimethoprim/sulfamethoxazolemethoxazole | ≤0.5/9.5 to >2/38 | >2/38 | >2/38 | |
| Tigecycline | 0.12 to 0.5 | 0.25 | 0.5 | |
| Levofloxacin | 0.12 to >4 | 4 | >4 | |
| Clindamycin | 0.12 to >16 | >16 | >16 | |
| Vancomycin | 1 to 4 | 1 | 1 | |
| Daptomycin | ≤0.5 to 2 | ≤0.5 | 1 | |
| Oxacillin | 1 to >4 | >4 | >4 | |
| Erythromycin | >8 | >8 | >8 | |
| Gentamicin | 0.25 to >16 | >16 | >16 |
a
Results for 4 epidemiological groups are not provided in the table because fewer than 10 isolates were tested. These were 1 isolate of ST45-MRSA-II (USA600), 3 isolates of ST72-MRSA-IV (USA700), 3 isolates of ST59-MRSA-IV (USA1000), and 3 isolates of ST30-MRSA-IV (USA1100).